SUMMARY Recently several assays have been developed which allow the growth of colonies from cell suspensions prepared from human tumour biopsy specimens. It has been suggested that such assays will provide a reliable means of measuring the chemosensitivity of human tumours for predicting the response to treatment in patients. We have briefly reviewed the previous, largely unsuccessful, attempts at chemosensitivity testing and the potential place of the new assays. The measurement of the survival of clonogenic tumour cells after cytotoxic treatment probably reflects to some extent the survival of cells which in vivo are capable of proliferating to repopulate and regrow the tumour. This endpoint therefore has advantages over alternatives that do not directly measure reproductive cell death, and the assays also have the advantage of suppressing the growth of many non-malignant cells found in tumours. However, technical problems such as the preparation of cell suspensions and the artificial nature of the drug exposure phase of the assays have not been completely overcome and the plating efficiencies remain low in most systems. Work with model systems such as human tumour xenografts tends to support the usefulness of the assays but also highlights some difficulties. Clinical studies of chemosensitivity testing are in progress and initial results are encouraging but inconclusive.
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The suggestion that laboratory tests performed with drugs directly on a patient's tumour might lead to the selection of appropriate cancer therapy for that patient has been made for many years.' It has drawn support from the analogy to infectious diseases where laboratory microbiological sensitivity tests have a major impact on clinical practice. However, the results of numerous attempts to develop a variety of different tests suitable for human cancers have been disappointing. Recently, assays have become available for the growth of colonies from cell suspensions of human tumour cells,2-5 and it has been suggested that these may form the basis of a new generation of chemosensitivity tests for human tumours.5 6 In this paper we present a brief review of the background to these studies and examine the potential and limitations of the clonogenic cell assays as predictive chemosensitivity tests.
Accepted for publication 22 October 1980 The rationale of chemosensitivity tests on individual human tumours Histopathological study divides human neoplasms into groupings which are of great importance in predicting response to chemotherapy. The striking contrast in the sensitivity of, for instance, Hodgkin's disease and malignant melanoma is well known. More detailed study using histochemical, immunological, and biochemical analysis of tumours of similar morphology can add considerably more information about the likely outcome of therapy. A chemosensitivity test on an individual tumour should define its place within a group of tumours which are histologically similar but heterogeneous in sensitivity. It is, therefore, complementary to knowledge derived from clinical studies of the overall response pattern of the group. The value of such a test must, therefore, be related to the degree of heterogeneity in sensitivity that exists to an agent within a group-of tumours which are not otherwise distinguishable. Clinical experience certainly suggests that substantial heterogeneity exists within many groups of tumours when they are treated with currently available agents: some patients respond while others do not. However, variations in drug pharmacokinetics and metabolism may be responsible for substantial differences between patients, and additional direct evidence that the tumours themselves are heterogeneous is necessary. Human tumours grown as xenografts in immune-deprived mice have proved useful experimental systems for the study of heterogeneity within tumour types, and a substantial body of evidence for its existence has emerged.7-9 An example of this kind of study is shown in Fig. 1 The ability to form colonies in semisolid media is regarded as a characteristic of malignant cells, and stromal cells which attach to culture dishes and grow as monolayers are unable to form colonies.65 However, colony formation is also a feature of haemopoietic precursor cells, stimulated lymphocytes, and macrophage precursor cells.66 67 Recently, it has been shown that experimental murine tumours may contain clonogenic macrophage precursor cells,68 which may also be present in human xenografts.9 Despite these other sources of clonogenic cells, the selectivity of cloning assays in soft media for tumour cells is one of their major advantages as putative chemosensitivity tests.
The low plating efficiencies obtained in most cloning assays when tumours are taken directly from patients may reflect the potential of the systems to select for subpopulations of cells. The results of chemosensitivity tests on these subpopulations could bemisleading. The likelihood that this is an important flaw in the assays is reduced by the observation that similar results are obtained when colonies are grown under widely differing culture conditions in soft agar or as lung colonies in immune-deficient mice.69 It is also reassuring that the chemosensitivity of tumour cells taken directly from a patient and tested in a cloning assay was similar to that of the human tumour xenograft, derived from the same biopsy, which grew with a higher plating efficiency70 (see Fig. 2 ). These studies provide some support to the hypothesis that cloning assays with low plating efficiencies may be representative of a tumour as a whole.
Two groups have used model systems to study the value of in vitro chemosensitivity assays based on cell cloning. An in vitro test was shown to predict the response of a murine experimental myeloma in vivo. 71 More recently, in vitro tests have been used to predict the in vivo response of human tumour xenografts. The in vitro sensitivity of cells of a human pancreatic carcinoma xenograft to a range of drugs correlated well with their sensitivity in the mouse. 39 However, in a later series of experiments using a series of melanoma xenografts the situation was less clear13 (Fig. 3) . Surviving fractions in the in vitro test correlated significantly with those in vivo for some drugs, and the in vitro test was able to predict which tumour would be most sensitive to a particular drug. However, the in vitro test did not reliably predict which drug would be most effective in vivo for a particular tumour, and it was notable that adriamycin was ineffective in vivo while achieving substantial cell kill in vitro. These failures probably reflected the difficulty in relating murine in vivo drug levels to the in vitro exposure concentrations (derived from human concentration x time data). 
